Objective. To determine the cost per quality-adjusted life-year for lumbar epidural steroid injections (LESI). Summary of Background Data. Despite being a widely performed procedure, there are few studies evaluating the costeffectiveness of LESIs. Methods. Patients who had received LESI between June 2012 and July 2013 with EuroQOL-5D (EQ-5D) scores available before and after LESIs but before any surgical intervention were identified. Costs were calculated on the basis of the Medicare Fee Schedule multiplied by the number of LESIs received between the 2 clinic visits. Quality-adjusted life-years (QALYs) were calculated using the EQ-5D. Results. Of 421 patients who had pre-LESI EQ-5D data, 323 (77%) had post-LESI data available; 200 females, 123 males, mean age: 59.2 AE 14.2 years. Cost per LESI was $608, with most patients receiving 3 LESIs for more than 1 year (range: 1-6 yr). Mean QALY gained was 0.005. One hundred forty-five patients (45%) had a QALY gain (mean ¼ 0.117) at a cost of $62,175 per QALY gained; 127 patients (40%) had a loss in QALY (mean ¼ À0.120) and 51 patients (15%) had no change in QALY. Fourteen of the 145 patients who improved, and 29 of the 178 patients who did not, have medical comorbidities that precluded surgery. Thirty-two (22%) of 131 patients without medical comorbidities who improved and 57 (32%) of 149 patients without medical comorbidities who did not improve subsequently had undergone surgery (P ¼ 0.015). Conclusion. LESI may not be cost-effective in patients with lumbar degenerative disorders. For the 145 patients who improved, cost per QALY gained was acceptable at $62,175.
L umbar epidural steroid injections (LESIs) are widely used as part of the nonsurgical treatment of lumbar degenerative disorders, radicular leg pain, or spinal stenosis at a rate of 2,055 of 100,000 Medicare enrollees in 2001. 1 The premise is that local injection of anti-inflammatory drugs, such as steroids, leads to a reduction of inflammation through inhibiting the formation and release of inflammatory cytokines, leading to pain reduction.
Recent systematic reviews and meta-analyses [2] [3] [4] [5] have concluded that strong evidence for the clinical efficacy of LESIs is lacking. Moreover, despite being a widely performed procedure, there are very few studies evaluating the cost-effectiveness of LESIs, [6] [7] [8] and most physicians remain unfamiliar with the standard evaluation tools that drive economic health care policy. The current measure for comparing the value of competing health care interventions is the cost per quality-adjusted life-year (cost per QALY) gained. 9, 10 Generally, interventions with a cost per QALY gained between $50,000 and $100,000, or less, are considered cost-effective. 11, 12 Interventions with a cost per QALY gained less than the country's per capita gross domestic product may also be considered cost-effective. 13 The purpose of this study is to determine the cost per QALY gained for LESIs. Secondary objectives are to determine whether LESIs decrease the risk of subsequent surgery and whether LESIs are effective in patients who have comorbid conditions precluding any surgical intervention.
MATERIALS AND METHODS
As part of standard clinical practice, the EuroQOL-5D-3 level (EQ5D-3L), 14 the Oswestry Disability Index (ODI), 15, 16 back pain scores (BP, 0-10), and leg pain scores (LP, 0-10) 17 are administered to all patients presenting with low back or lower extremity complaints. This includes both surgical and nonsurgical patients seen at a single tertiary spine center with 6 spine fellowship-trained surgeons with similar practice patterns, representing a typical adult spine practice population. After receiving institutional review board approval, patients who had a LESI between June 2012 and July 2013 and had EQ-5D 14 and ODI 15, 16 scores available before and after LESIs, but before any surgical intervention, were identified. Two anesthesiologists performed all LESIs. Costs were calculated on the basis of the Medicare fee schedule multiplied by the number of LESIs received between the 2 clinic visits. Because there were no formal follow-up periods and the EQ-5D and ODIs were administered at varying time intervals in each patient, the calculation of QALYs was adjusted for the length of followup. The primary analysis was carried out using EQ-5D health state utility values. A secondary analysis calculating QALY on the basis of the SF-6D derived from the ODI 18 was also performed.
RESULTS
Of the 421 patients who had received a LESI and had EQ-5D and ODI data prior to the first LESI, 323 (77%) had EQ-5D and ODI data after their LESI but before any surgical intervention. There were 200 females and 123 males with a mean age of 59.2 AE 14.2 years (range, 18-88 yr). There were 6 (2%) patients who were being treated under Workman's Compensation. The preinjection and postinjection outcomes are summarized in Table 1 . Although there was a statistically significant difference between all preinjection and postinjection clinical outcomes, the magnitude of change is small.
Cost per LESI was $608, with most patients receiving 3 LESIs over the span of 1 year (range: 1-6 yr) ( Table 2 ). The mean cumulative QALY gained was 0.005 using the EQ-5D. The EQ-5D gained was similar regardless of which anesthesiologists performed the procedure (P ¼ 0.402). The cost per QALY gained for the entire cohort was $249,631. One hundred forty-five patients (45%) had a gain in QALY (mean ¼ 0.117) at a cost of $62,175 per QALY gained, 127 (40%) had a loss in QALY (mean ¼ À0.120), and 51 (15%) had no change in QALY. There was no difference (P ¼ 0.548) in the distribution of specific spine pathologies between the patients who had a gain in QALY compared with those who did not ( Table 3 ). The preoperative ODI and back and leg pain scores were similar in the patients who had a gain in QALY and those who did not ( Table 4 ).
Fourteen of the 145 patients who improved, and 29 of the 178 patients who did not, had medical comorbidities that precluded surgery. These 43 patients who had comorbid conditions precluding surgery had a loss in QALYs, with a mean change in QALY of À0.017. Thirty-two (22%) of 131 patients without medical comorbidities who improved and 57 (32%) of the 149 patients without medical comorbidities who did not improve subsequently had undergone surgery. This proportion is statistically significantly different at P value of 0.015. Although the patients who had undergone surgery even after improvement with LESI had a lower mean QALY gain (0.105) than those who did not undergo surgery (0.118), this was not statistically significant (P ¼ 0.635).
The mean cumulative QALY based on the SF-6D gained was 0.005, with similar gains between the 2 anesthesiologists (P ¼ 0.658). For the entire cohort, the cost per QALY gained on the basis of SF-6D utilities is $273,624. One hundred sixty-five patients (51%) had a gain in QALY (mean ¼ 0.117) at a cost of $114,110 per QALY gained, 138 (43%) had a loss in QALY (mean ¼ À0.119), and 20 (6%) had no change in QALY. Seventeen of the 165 patients who improved, and 26 of the 158 patients who did not, had medical comorbidities that precluded surgery. These patients who had comorbid conditions precluding surgery had a loss in QALYs, with a mean change in QALY of À0.015. Forty-three (29%) of 148 patients without medical comorbidities who improved and 50 (38%) of the 132 patients without medical comorbidities who did not improve subsequently had undergone surgery. This proportion is not statistically significantly different at P value of 0.128. Although the patients who had undergone surgery even after improvement with LESI had a lower mean QALY gain (0.036) than those who did not undergone surgery (0.040), this was not statistically significant (P ¼ 0.635). A sensitivity analysis looking at the number of steroid injections necessary to make LESI cost-effective in patients with a gain in QALY showed that 3 or less injections would be costeffective when EQ-5D valuations accrued and 2 injections or less when SF-6D valuations are used ( Table 5 ). In addition, even with an increase in the number of LESIs administered, the change in EQ-5D score or SF-6D score was similar ( Table 6 ).
DISCUSSION
Recent systematic reviews evaluating the comparative effectiveness of LESIs showed that the best available evidence regarding its efficacy is less than robust. [2] [3] [4] [5] These systematic 19 type, 20, 21 or dose 22, 23 of steroid, or are limited by a lack of a true placebo group. [24] [25] [26] Earlier studies 26, 27 comparing epidural steroid with epidural saline injections showed a significant improvement at 3 weeks in patients receiving epidural steroid injections. However, by 6 weeks, the benefit of steroid injections was no longer evident. A more recent randomized placebo controlled trial comparing epidural steroid, epidural saline, and sham showed no differences in outcomes among the 3 groups at any follow-up time point up to 1 year postinjection. 28 The current study was undertaken to further evaluate the cost-effectiveness of lumbar epidural injections in a pragmatic clinical study. Performing a pragmatic study allows the clinician to assess the role of LESIs in the management of patients with lumbar degenerative disorders. QALYs were not determined on the basis of specific predetermined time points but were adjusted on the basis of standard of care clinical follow-up, allowing for real-world evaluation of the efficacy of LESI. Despite the lack of formal follow-up time points, the results of the current study were similar or better than previously published prospective studies, [26] [27] [28] [29] [30] with around half of the patients showing improvement.
However, with only half of patients showing improvements or a gain in QALY, it would be difficult to conclude that LESIs are cost-effective in patients, based upon commonly accepted indications. Looking at outcome measures, there was a statistically significant improvement in ODI and back and leg pain scores, but none of these would be considered clinically meaningful. The mean improvement in ODI was 3.5 points and mean improvement in back and leg pain was less than 1 point, none of which are clinically relevant. 31 Adjusting for inflation and converting to US dollars, Udeh et al 8 reported a cost per QALY of $37,758, Whynes et al 7 reported $48,537, and Price et al 6 reported $94,000 for LESIs. Considering only patients who had a gain in QALY based on the EQ-5D, the cost per QALY calculated in this study of $62,175 was cost-effective. However, when QALY based on the SF-6D is used, the cost per QALY gained of $114,110 for patients who improved is above the threshold considered to be cost-effective. 11, 12 The mean change in SF-6D was only a third of the mean change in EQ-5D. This is consistent with previously published studies that have shown that the gain in utility when measured using the SF-6D is smaller than when measured by the EQ-5D. 32 In contrast to other studies, 26, 27 in this study, a statistically greater proportion of patients who did not improve with LESIs on the basis of their EQ-5D (32%) elected to undergo surgery compared with those who improved (22%). Based on these data, it would seem that some patients improved enough with LESI that they deemed surgery unnecessary. However, if SF-6D valuations are used, this is not true. That is, the proportion of patients who elected to undergo surgery was similar in those who had improvements in SF-6D (38%) compared with those who did not (29%). Although it may be argued that these patients may not have been surgical candidates, the proportion of patients with nonspecific back pain was similar in patients who had EQ-5D improvements and those who did not, and the mean preinjection ODI score was in the ''severe disability'' category for ODI.
In patients who had comorbid conditions precluding surgery, there was a relatively small loss in QALY even after a LESI. It would be difficult to ascertain whether these patients would have deteriorated even further, with greater losses in QALYs if they did not have received any LESIs. For the same reason, it would be difficult to ascertain whether patients who improved with LESIs would have improved spontaneously, even without LESIs. Current practice guidelines recommend that the number of LESIs be tailored on the basis of the individual patient response. 24, 33 A recent literature review, however, showed that most providers perform a series of LESIs. 34 In the current study, 94% of patients received 3 or less injections. There does not seem to be a rational use of increasing number of injections because there was no difference in the EQ-5 D or SF-6 D scores stratified by number of LESIs performed. Based on the current data, administration of 1 or at the most 3 LESIs may be cost-effective. Additional LESIs do not seem to increase effectiveness despite the additional cost.
There are limitations to the study. Patients were seen at a tertiary spine specialty clinic, which may introduce selection bias, including patients who are more symptomatic and may have less response to LESIs. The diagnostic etiology prompting treatment with LESI was heterogeneous. However, the distribution of the different diagnostic etiologies was similar between the patients who improved and those who did not. Moreover, recent studies from a single group of authors have shown no difference in outcomes between LESI and control patients with disc herniation and radiculitis, 35 discogenic pain without disc herniation or radiculitis, 36 postsurgery syndrome, 37 and spinal stenosis. 38 The EQ-5D that is considered a long-ordinal scale with only 243 health states valued may not be sensitive enough to detect a change in health states in this specific population. 14 Although not specifically monitored and collected, the volume, dose, and frequency of LESIs probably varied from patient to patient. This is not different from normal routine care. Only 2 specific anesthesiologists performed all the LESIs. This was done to mitigate a possible large amount of variation in technique. The results from this study showed that there was no difference in the amount of QALY gained between the 2 anesthesiologists.
This study indicates that based on existing indications for treatment, LESI is not a cost-effective intervention. This stems from the fact that only 45% of patients obtained clinical benefit and that the magnitude of improvement was modest. Examination of the subset that obtained clinical benefit demonstrated the potential for cost-effectiveness because this group had a cost per QALY of $62,175 on the basis of EQ-5D utility values. However, an alternative analysis using SF-6D utility values did not demonstrate costeffectiveness, even in the clinical responders at a cost per QALY of $114,110. These findings emphasize the need to use LESI in a more targeted and judicious fashion. LESI is often advocated simply because it is not surgery. However, our data indicate that, even in the patients who obtained clinical benefit, surgical treatment was only marginally less frequent. Furthermore, recent studies indicate that presurgical LESI may diminish the benefit of subsequent surgical treatment. 39, 40 In summary, LESIs are not being used in a cost-effective manner. Although there seems to be a subset of patients who benefit from LESI, that group needs to be more clearly defined. Even if the majority of patients improve after LESI, cost-effectiveness would still be dependent upon durability and the frequency at which injections are required.
Key Points
Although a statistically significant improvement in ODI and back and leg pain scores was seen post-LESI, none of these improvements would be considered clinically significant. Only 45% of patients who had received a lumbar epidural steroid injection had a gain in health state utility. For the entire group, the cost per QALY gained on the basis of the EQ-5D was $249,631. For the patients who improved, cost per QALY based on the EQ-5D gained was acceptable at $62,175. When QALY is calculated using the SF-6D, the cost per QALY gained for the entire group was $273,624. Even if only patients who had improvement were considered, LESIs may still be cost-prohibitive at a cost per QALY gained of $114,110. For the majority of patients with no gain or a loss in QALY, the economics cannot be reported with a cost per QALY gained being theoretically infinite.
